The combination of pleconaril, rupintrivir, and remdesivir efficiently inhibits enterovirus infections in vitro, delaying the development of drug-resistant virus variants.
Animals
Humans
Enterovirus A, Human
Enterovirus
Enterovirus Infections
/ drug therapy
Enterovirus B, Human
Antiviral Agents
/ pharmacology
Drug Combinations
Adenosine Monophosphate
/ analogs & derivatives
Oxadiazoles
Pyrrolidinones
Oxazoles
Valine
/ analogs & derivatives
Isoxazoles
Phenylalanine
/ analogs & derivatives
Alanine
/ analogs & derivatives
Antiviral drug combination
Antiviral strategy
Broad-spectrum antiviral agent
Echovirus
enterovirus
Journal
Antiviral research
ISSN: 1872-9096
Titre abrégé: Antiviral Res
Pays: Netherlands
ID NLM: 8109699
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
03
01
2024
revised:
10
02
2024
accepted:
24
02
2024
medline:
18
3
2024
pubmed:
29
2
2024
entrez:
28
2
2024
Statut:
ppublish
Résumé
Enteroviruses are a significant global health concern, causing a spectrum of diseases from the common cold to more severe conditions like hand-foot-and-mouth disease, meningitis, myocarditis, pancreatitis, and poliomyelitis. Current treatment options for these infections are limited, underscoring the urgent need for effective therapeutic strategies. To find better treatment option we analyzed toxicity and efficacy of 12 known broad-spectrum anti-enterovirals both individually and in combinations against different enteroviruses in vitro. We identified several novel, synergistic two-drug and three-drug combinations that demonstrated significant inhibition of enterovirus infections in vitro. Specifically, the triple-drug combination of pleconaril, rupintrivir, and remdesivir exhibited remarkable efficacy against echovirus (EV) 1, EV6, EV11, and coxsackievirus (CV) B5, in human lung epithelial A549 cells. This combination surpassed the effectiveness of single-agent or dual-drug treatments, as evidenced by its ability to protect A549 cells from EV1-induced cytotoxicity across seven passages. Additionally, this triple-drug cocktail showed potent antiviral activity against EV-A71 in human intestinal organoids. Thus, our findings highlight the therapeutic potential of the pleconaril-rupintrivir-remdesivir combination as a broad-spectrum treatment option against a range of enterovirus infections. The study also paves the way towards development of strategic antiviral drug combinations with virus family coverage and high-resistance barriers.
Identifiants
pubmed: 38417531
pii: S0166-3542(24)00050-0
doi: 10.1016/j.antiviral.2024.105842
pii:
doi:
Substances chimiques
pleconaril
9H4570Q89D
rupintrivir
RGE5K1Q5QW
remdesivir
3QKI37EEHE
Antiviral Agents
0
Drug Combinations
0
Adenosine Monophosphate
415SHH325A
Oxadiazoles
0
Pyrrolidinones
0
Oxazoles
0
Valine
HG18B9YRS7
Isoxazoles
0
Phenylalanine
47E5O17Y3R
Alanine
OF5P57N2ZX
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
105842Informations de copyright
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.